Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 30/08/2010 12218_de.jpg

    Bodensee Brustzentrum offers effective breast cancer prevention services

    The two Brustzentrum Bodensee (Lake Constance Breast Centre) sites at the Hospital in Constance and the Women’s Hospital in Friedrichshafen have a principal goal: to enable the best possible early detection of all types of breast cancer, to reduce the morbidity and mortality of breast cancer patients and to increase survival rates by offering ultra-modern breast cancer prevention measures.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bodensee-brustzentrum-offers-effective-breast-cancer-prevention-services
  • Press release - 12/08/2010

    Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First Patients in Clinical Trial

    Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetu
  • Press release - 08/08/2010

    Human protein produced in a moss bioreactor

    The research group led by Prof. Ralf Reski is a moss specialist and has now, for the first time, succeeded in producing a human protein in a moss bioreactor – the complement factor H. The lack of this protein leads to age-related macular degeneration in about 50 million people worldwide. The complement factor H has been assigned ‘orphan drug’ status by the respective EU authorities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/human-protein-produced-in-a-moss-bioreactor
  • Press release - 02/08/2010 12014_de.jpg

    Stephanie Combs – excellent research on the treatment of brain tumours

    Dr. Stephanie Combs radiooncologist at the University of Heidelberg was awarded the Hermann Holthusen Prize for her achievements in improving the treatment of malignant brain tumours. The prize which comes with a purse of 5000 euros is the most prestigious prize in the field of radiooncology in Germany. Dr. Combs received the prize from the German Society of Radiooncology DEGRO at its annual meeting held in Magdeburg in June 2010. Dr. Combs most…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/stephanie-combs-excellent-research-on-the-treatment-of-brain-tumours
  • Press release - 22/06/2010

    CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer

    CureVac GmbH, the mRNA company, today announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer (NSCLC).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-iia-with-mrna-immunotherapeutic-in-non-small-cell-lung-cancer
  • Press release - 02/06/2010

    immatics enters Collaboration with the National Cancer Institute (NCI)

    immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-enters-collaboration-with-the-national-cancer-institute-nci
  • Press release - 14/05/2010 Computer simulation of the surface structure of a parvovirus

    Viruses against cancer: complete regression of malignant brain tumours after treatment with parvoviruses

    Studies by scientists from the German Cancer Research Centre (DKFZ) have shown that advanced glioblastomas regressed completely in rats after treatment with parvoviruses, thus significantly increasing the survival time compared with untreated animals. Parvoviruses do not cause any disease symptoms in humans and the rats treated did not show any undesired side effects, either. A clinical phase I trial on parvovirus treatment of patients with…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/viruses-against-cancer-complete-regression-of-malignant-brain-tumours-after-treatment-with-parvoviru
  • Press release - 23/04/2010 The picture shows the cover of the German Biotechnology Report 2010.

    Ernst & Young: "German Biotechnology Report 2010"

    During the global crisis in 2009, the revenues, number of companies and the number of employees in the German biotechnology industry remained unchanged from the previous year. However, considerable progress was made in terms of product development and market admissions. As in the previous year, 2009 saw a strong slump in terms of equity financing. Investments in research and developments fell. Collaborations and strategic alliances acted as…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ernst-young-german-biotechnology-report-2010
  • Press release - 15/04/2010 10084_de.jpg

    Nycomed and Baxter receive FDA approval for TachoSil®

    Today Nycomed and its partner Baxter International Inc. NYSE BAX received the approval for TachoSil a surgical patch from the US Food and Drug Administration FDA. TachoSil has been approved as an adjunct to haemostasis control of bleeding in cardiovascular surgery.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-baxter-receive-fda-approval-for-tachosil
  • Press release - 12/03/2010 logo of mtm

    mtm laboratories announces the European launch of CINtec® PLUS

    mtm laboratories, a privately held diagnostics company from Heidelberg, Germany, announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-announces-the-european-launch-of-cintec-plus
  • Press release - 18/02/2010 10739_de.jpg

    New molecules promise improved diagnosis of pancreatic cancer

    Being diagnosed with pancreatic cancer is often a death sentence. One reason for the high mortality rate of pancreatic cancer patients is that there is currently no reliable diagnosis of early stages and no cure once the disease has reached a late stage. In an EU-funded project, 23 research groups from six countries have developed new strategies for the improved diagnosis of pancreatic cancer. Researchers at the Ulm-based Hospital for Nuclear…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecules-promise-improved-diagnosis-of-pancreatic-cancer
  • Press release - 26/01/2010 Logo apogenix

    Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma

    Apogenix GmbH, a biopharmaceutical company today announced the start of a clinical Phase II trial with its lead compound AGP101 in Glioblastoma Multiforme (GBM). The first patient has been treated with APG101 since December 2009 at the University Hospital in Heidelberg, Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-initiates-clinical-phase-ii-study-with-its-lead-compound-apg101-in-glioblastoma
  • Article - 25/01/2010 Prof. Dr. Martin Elmlinger and his colleague Marion Eisenhauer in the laboratory. Elmlinger is holding a ball-pen in his hand, pointing at a microtitre plate Marion Eisenhauer is holding in her hand.<br />

    Intelligent use of suitable biomarkers

    How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…

    https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
  • Article - 25/01/2010 10444_de.jpg

    Hope for effective ulcerative colitis treatment

    Ulcerative colitis, a chronic form of inflammatory bowel disease, is characterised by a reduced amount of the lipid phosphatidylcholine in the colon mucosa. This fact was discovered by Wolfgang Stremmel and his team at the University Hospital of Heidelberg. In collaboration with the Heidelberg-based biotechnology company Lipid Therapeutics, the researchers are now working on the development of a phosphatidylcholine drug for the treatment of this…

    https://www.gesundheitsindustrie-bw.de/en/article/news/hope-for-effective-ulcerative-colitis-treatment
  • Article - 18/01/2010 <br /> <br />

    New substance helps PKU patients enjoy food

    For many decades, a special low-protein (low-phenylalanine) diet has been the only way of treating children suffering from phenylketonuria (PKU) that effectively prevents them from developing severe impairments in mental function. However, this type of diet is not very tasty and it is often difficult to get children to cooperate. A paediatrician from Reutlingen, Prof. Dr. Friedrich Trefz, has now been able to show that the substance sapropterin…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-substance-helps-pku-patients-enjoy-food
  • Press release - 13/11/2009 10079_de.jpg

    Single molecules under the laser: How the genetic material is unwrapped

    The genetic material found in cells is not in its free state, but is bound to large protein complexes and tightly wrapped. To activate genes that could well play a role in carcinogenesis, the genetic material first needs to be unwrapped and made accessible to other cell components. Using a new biophysical method called single molecule spectroscopy, scientists from the “Biophysics of Macromolecules” division at the German Cancer Research Centre…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/single-molecules-under-the-laser-how-the-genetic-material-is-unwrapped
  • Press release - 11/11/2009 10061_de.jpg

    Hematopoietic stem cell treatment with a new gene therapy vector: A first success treating a brain disease

    Two children with adrenoleukodystrophy (ALD), a fatal brain disease, have been successfully treated with a new gene therapy vector. Two years after treatment, the disease evolution has been stopped, and no adverse effect of the gene therapy has been observed so far. The results of this clinical trial conducted by Drs Nathalie Cartier and Patrick Aubourg (Inserm, France) in collaboration with European partners have just been published in Science…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hematopoietic-stem-cell-treatment-with-a-new-gene-therapy-vector-a-first-success-treating-a-brain-di
  • Press release - 05/11/2009 09981_de.jpg

    Canadian companies to establish contacts with potential Baden-Württemberg partners

    At a Canadian-German partnering event held on 29th October 2009 in Stuttgart, a number of Canadian and German companies presented themselves to an audience of representatives from industry, business associations and politics. The partnering event was jointly organised by the Canadian Consulate and BIOPRO Baden-Württemberg.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/canadian-companies-to-establish-contacts-with-potential-baden-wuerttemberg-partners
  • Press release - 21/10/2009 09805_de.jpg

    Meyenburg Award 2009 for the First Targeted Anti-Cancer Drug

    The 2009 Meyenburg Award for Cancer Research with an award sum of 50,000 euros goes to American blood cancer expert, Brian Druker. The Meyenburg Foundation honors Druker as a pioneer of molecularly targeted cancer therapies for developing the leukemia drug Imatinib (Gleevec). Druker’s work has turned chronic myeloid leukemia from a deathly threat into a treatable disease for many patients today. The Meyenburg-Award has been presented on…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/meyenburg-award-2009-for-the-first-targeted-anti-cancer-drug
  • Press release - 19/10/2009

    New ulcerative colitis therapy in sight

    Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ulcerative-colitis-therapy-in-sight
  • Press release - 18/09/2009

    Why don’t brain tumours respond to drugs?

    Malignant brain tumours do not often respond to promising new drugs. Researchers from Heidelberg have now uncovered a mechanism and a tumour marker that are linked to the development of this resistance. A “death receptor” might possibly indicate the chances of success of chemotherapy at the same time as providing new approaches for developing a new therapy for the successful treatment of brain tumours.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-don-t-brain-tumours-respond-to-drugs
  • Press release - 18/09/2009

    Affimed Therapeutics AG receives FDA Orphan Drug Designation for AFM13 against Hodgkin Lymphoma

    Affimed Therapeutics AG announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to the human recombinant antibody AFM13 for the treatment of Hodgkin lymphoma. The designation entitles Affimed to seven-year market exclusivity in the US upon approval of this drug candidate. AFM13 is a novel, bispecific antibody based on Affimed's proprietary TandAb technology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-therapeutics-ag-receives-fda-orphan-drug-designation-for-afm13-against-hodgkin-lymphoma
  • Article - 21/08/2009 09395_de.jpg

    Patenting and clinical trials go hand in hand

    Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…

    https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
  • Press release - 30/07/2009

    Boehringer Ingelheim set to outpace the market again

    After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
  • Press release - 28/07/2009 09030_de.jpg

    New trachea made from human tissue

    A team of doctors from the Schillerhöhe Hospital, which is part of the Robert Bosch Hospital in Stuttgart, in cooperation with researchers from the Fraunhofer Institute of Interfacial Engineering and Biotechnology IGB in Stuttgart, has developed a method that enables artificially produced autologous tissue to be implanted into patients with severe tracheal injuries. The method involves the cultivation of extensive parts of the human trachea and…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-trachea-made-from-human-tissue

Page 8 / 10

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2022
Website address: https://www.gesundheitsindustrie-bw.de/en/search